anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Turmeric extracts and curcumin have been shown to be safe, even at high doses without significant side-effects. Previous clinical studies in other inflammatory skin diseases have shown that a dosage of curcumin at 6,000 mg daily was effective while lower doses were not. In a human phase I clinical trial examining the effects of high dose curcumin in preventing premalignant lesions, even curcumin doses as high as 8,000 mg/day resulted in no toxic effects after 3 months. This study will involve participant ingestion of 6,000 mg/day of turmeric or curcumin to assess how this affects their sebum production.

The investigators will also be collecting stool from the study subjects, and examining how the curcumin and turmeric may modulate their gut microbiome. The investigators will specifically be looking to see if curcumin or turmeric have any changes on the gut flora towards bacteria that produce more short chain fatty acids. Certain bacteria that make up the microbiome produce short chain fatty acids, such as butyrate and propionate, which have demonstrated anti-inflammatory properties. Thus, it would be interesting to see if turmeric or curcumin exert any of its anti-inflammatory effects via modulation of the microbiome.
Tenofovir is principally eliminated by the kidney. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of VIREAD [see Adverse Reactions (6.2)].

Prior to initiation and during use of VIREAD, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.

Dosing interval adjustment of VIREAD and close monitoring of renal function are recommended in all patients with creatinine clearance below 50 mL/min [see Dosage and Administration (2.3)]. No safety or efficacy data are available in patients with renal impairment who received VIREAD using these dosing guidelines, so the potential benefit of VIREAD therapy should be assessed against the potential risk of renal toxicity.

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1)]. Cases of acute renal failure after initiation of high dose or multiple NSAIDs have been reported in HIV-infected patients with risk factors for renal dysfunction who appeared stable on TDF. Some patients required hospitalization and renal replacement therapy. Alternatives to NSAIDs should be considered, if needed, in patients at risk for renal dysfunction.

Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in patients at risk of renal dysfunction.
Tumor heterogeneity and tumor clonal evolution cause he diagnosis and treatment difficulties of advanced prostate cancer. Heterogeneity exists in different lesions at the same location of the same tumor, between lesions at different locations, and in the same lesion in different processes of disease progression. Tumor heterogeneity causes different tumor patients to respond differently to different treatments; as patients progress, tumor patients gradually develop clonal evolution, and the original effective treatment will lose the therapeutic effect. And routine imaging examinations and PSA examinations are also difficult to respond to changes in the patient's condition in a timely manner. By Genetic testing of the primary tumor, metastases or blood of the patient, and according to the test result of the patient, the patient's medication treatment can be provided, and the patient's condition change can be monitored. Studies have shown that patients with different mutation types respond differently to the same treatment. Prostate cancer patients with AR-V7 mutations have a poorer response to abiraterone or dextrozamide than patients with prostate cancer without AR-V7 mutation; whereas for solid tumors with MSI-H or dMMR, PD-1 Inhibitors can also bring the desired results to such patients. Therefore, according to the genetic test results of the patient's tumor tissue, early diagnosis can also be given, and the patient's condition change and precise treatment can be predicted.In this study, the investigators hope to obtain the genome characteristics of advanced patients by performing whole exon sequencing on the patient's tissues, and to guide the patients' follow-up treatment through sequencing results, to observe the effects of different treatment methods on patients and find biomarker that predict patient prognosis
NEW MATERIAL:A compound of the formula (R is H or OH). USE:Useful as a medicine, e.g. a cancer eliminating agent, and having a powerful ability to induce the differentiation of human myelocytic leukemia HL-60 cells into granulocytes. PROCESS:Vitamin D3 or 25-hydroxyvitamin D3 is reacted with a peroxide, e.g. the reaction of tert-butyl hydroperoxide with vanadyl acetylacetonate, in an inert solvent, e.g. benzene, to give the compound of the formula.
Sarcoidosis is a multisystem granulomatous disease of unknown cause. Although sarcoidosis most commonly affects the lung3, it may affect any organ. Although corticosteroids are recognized as the drug of choice for sarcoidosis, ACTH is the only drug that is FDA-approved for this disorder. However, there is limited data on the efficacy of ACTH for this condition.

Presently, corticosteroids as considered the drug of choice for the treatment of cutaneous sarcoidosis. However, ACTHER GEL not only has obvious anti-inflammatory effects by resulting in corticosteroid production, but it may also activate melanocortin receptors. The melanocortin system has powerful anti-inflammatory properties that may be beneficial in the treatment of cutaneous sarcoidosis.
Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
Osteoarthritis (OA) represents a significant global health burden without a known disease modifying agent thereby necessitating pursuit of innovative therapeutic approaches. The infrapatellar fat pad (IFP) serves as a reservoir of mesenchymal stem/stromal cells (MSC), and with adjacent synovium plays key roles in joint disease affecting local inflammatory responses. Therapeutically, IFP-MSC have garnered attention for their potential in OA treatment due to their immunomodulatory and regenerative properties. However, optimizing their therapeutic efficacy necessitates a comprehensive understanding of how growth medium and inflammatory/hormonal priming influence their behavior. In this study, we isolated and expanded IFP-MSC in three different growth media: DMEM + 10% fetal bovine serum (FBS), DMEM + 10% human platelet lysate (HPL), and xeno-/serum-free synthetic (XFSF) medium. Subsequently, cells were induced with an inflammatory/fibrotic cocktail (TIC) with or without oxytocin (OXT). We evaluated various parameters including growth kinetics, phenotype, immunomodulatory capacity, gene expression, and macrophage polarization capacity. Our results revealed significant differences in the behavior of MSC cultured in different media. IFP-MSC cultured in HPL and XFSF exhibited superior growth kinetics and colony-forming abilities compared to those cultured in FBS. Furthermore, both HPL and XFSF media enhanced the expression of MSC markers (> 90%) and potentiated their immunomodulatory properties. Notably, XFSF-conditioned IFP-MSC demonstrated the highest attenuation of peripheral blood mononuclear cell (PBMC) proliferation, indicating their robust immunosuppressive capacity. Additionally, TIC priming further augmented the immunomodulatory functionality of MSC, with IFP-MSC exhibiting enhanced suppression of PBMC proliferation upon TIC priming. Of particular interest, gene expression analysis revealed distinct patterns in TIC + OXT induced MSC compared to TIC only induced, with upregulation of genes associated with immunomodulatory and regenerative functions. Furthermore, TIC + OXT priming promoted M2 polarization in macrophages, suggesting a potential therapeutic strategy for immune-mediated inflammatory joint conditions including OA. Our findings highlight the critical influence of growth medium and inflammatory/hormonal priming on MSC behavior and therapeutic potential. XFSF and HPL media offer promising alternatives to FBS, enhancing MSC growth and immunomodulatory properties. Moreover, TIC + OXT priming represents a novel approach to augment MSC immunomodulation and promote M2 polarization, providing insights into potential therapeutic strategies for OA and other immune-mediated inflammatory conditions.
FIELD: medicine. SUBSTANCE: proposed carrier has formed detail which contains form-storing substance and substance which may be destroyed by biological means. Said substances are used as compound or as a mixture. Mentioned above detail has such a size and strength that it is well preserved into stomach within predetermined period. Said carrier has such a shape that it does not prevent in passing food into stomach, it also may be used as a system for applying remedy. Proposed carrier may have film covering. EFFECT: improves quality of desired product. 4 cl, 9 dwg, 16 tbl
Health care professionals can enhance conversations about serious illness and medical decision-making by adopting a transparent, standardized approach. This article critiques established communication strategies, which often emphasize patient values and goals without providing the necessary medical information to align these goals with a shared understanding of prognosis. We propose an alternate strategy that (1) provides detailed explanations of medical conditions at the beginning of the conversation, (2) includes support persons in discussions, (3) considers capacity, and (4) offers tailored advice by clinicians. The proposed framework aims to provide patients (or their delegates) with the information they need to integrate their values in pursuit of well-informed medical decisions. This strategy builds trust by providing honest information about medical conditions and their trajectories. It empowers decision makers to consider realistic outcomes, allowing them to accept or reject treatments in accordance with their preferences. This article presents a thorough step-by-step guide on how to conduct a serious illness conversation and facilitate medical decision-making, including a supplement that provides example phrases for use in clinical practice.
Control Group: Nurses who met the criteria for participating in the study were informed about the study and their consent was obtained. Data collection forms were collected by the researcher at the end of the working hours. No training was given to the control group. However, after the post-test application was made to the control group, the same training was given to the experimental group. One month later, data collection forms were distributed to the nurses in the control group and they were asked to fill in according to their self-reports. Data collection forms were collected by the researcher at the end of the working hours. Filling in the data takes about 15 minutes.
The invention provides a culture cage for reducing disinfection time between chickens coming in and out of a cage. The culture cage comprises a frame, a cage and an egg conveying belt. The cage is of a cube structure formed by a front side board, a back side board, a bottom board, an upper side board and two side boards, wherein a drawing rail is fixed on the two sides of the bottom of a front face board. The drawing rail is slidably connected with the side boards. A limiting board is fixed on the upper portion of the front face board, and the limiting board is slidably connected with the upper side board. A hydraulic rod is fixed on the upper portion of the back side board, an output end of the hydraulic rod is provided with a mobile frame, and the lower surface of the mobile frame is provided with a plurality of ultraviolet lamps. Active ingredients of disinfecting drug in a medicine kettle of a liquid inlet pipe on the upper side board comprise angelica dahurica of 60-90 g, fructus cnidii of 60-90 g, gentiana macrophylla of 60-90 g, magnolia officinalis of 30-50 g, radix sileris of 30-50g, croton seed of 30-50 g, trichosanthes kirilowii maxim of 30-50 g, mint of 30-50 g , dragon's blood of 30-50 g, realgar of 15-30 g, zanthoxylum of 15-30 g, lycoperdon bovista of 15-30 g, equisetum hiemale stem of 15-30 g, mulberry leaf of 15-30 g, ginger of 15-30 g, dark plum of 15-30 g, chrysanthemum of 10-20 g, hydrargyrum oxydatum crudum of 15 g and 20% glutaraldehyde solution of 15 g. The culture cage is simple in structure, convenient to use and good in chicken coming out effect, chicken bodies and the vacated cage are disinfected synchronously when the chickens come out of the cage, and the pollution rate of pathogenic bacteria is reduced.
A skin treatment agent contains a bilayer source, salts of organic acids, alcohol, stabiliser and lipids. USE/ADVANTAGE - The skin treatment agent has a high lipid content and can be used in cosmetics and dermatology. The agent does not have the problems associated with previous similar liposome prepns. (e.g. irritation due to high emulisifer concns. removal from the skin on washing). The bilayer is capable of building up the damaged lipid double layers in the epidermis and includes lipids in these layers, which are normally present in the epidermis. Thus skin quality (e.g. moisture, softness, reduction of transdermal water loss, improvement in the depot effect of the epidermis for dermatological active ingredients) is improved.
Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
A system, apparatus, and method to monitor at least one person in at least one environment. A care processing system receives data from at least one sensor in an environment for a monitoring a person under care. The data received is matched to a pattern for such data configured by the signal processing system. Upon the matching of such data, at least a first sensor creates an event that in whole or in part matches such pattern. The signal processing configures a first sensor to collect data created by such event, or instructs a second and subsequent set of sensors to collect data about the event, such that signal processing may determine the accuracy of such data for matching of the pattern. The situation is represented for a monitored person in an environment for the purpose of providing care to that person.
The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
Opioid agonist treatment (OAT) is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia.

The CoLAB study is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32mg of sublingual buprenorphine (+/- naloxone), participants will receive monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience. Qualitative and costing sub-studies will examine implementation barriers and facilitators at the client and provider level.
The invention discloses colorectal cancer tumor boundary cell subset biomarker and application thereof in diagnosis, prevention, treatment and prognosis. The invention also discloses a micro-environment cytogram of the cancer side and cancer tissues of the intestinal cancer patient, wherein the intestinal cancer tissuesSpecific enrichment of FAP  +  Fibroblast and SPP1  +  Macrophages. The invention also discloses FAP  +  Fibroblast and SPP1  +  Cellular markers of macrophages. The present invention further discloses that patients who found high expression of these two proteins in the bladder cancer dataset also had lower responsiveness to PD-L1 treatment. The invention also discloses FAP  +  Fibroblast and SPP1  +  Macrophages are also spatially located close in intestinal cancer and form a "wall" like tumor boundary around the tumor center, preventing immune cells from entering the tumor center. Through the cell characteristics and the cell interaction mode, CRC can be effectively diagnosed, prevented, treated, estimated for prognosis survival rate and the like.
PURPOSE: Lateral sleep position has a significant beneficial effect on the severity of Cheyne-Stokes respiration with central sleep apnea (CSR-CSA) in patients with heart failure (HF). We hypothesized that a reduction in rostral fluid shift from the legs in this position compared with the supine position may contribute to this effect.
METHODS: In patients with CSR-CSA and an apnea-hypopnea index (AHI) ≥ 15/h (by standard polysomnography), uncalibrated leg fluid volume was measured in the supine, left lateral decubitus, and right lateral decubitus positions (in-laboratory assessment). The correlation between postural changes in fluid volume and corresponding changes in AHI was evaluated. Since there was no difference in both leg fluid volume and AHI between the right and left positions, measurements in these two conditions were combined into a single lateral position.
RESULTS: In 18 patients with CSR-CSA, leg fluid volume increased by 2.7 ± 3.1% (p = 0.002) in the lateral position compared to the supine position, while AHI decreased by 46 ± 20% (p < 0.0001) with the same postural change. The correlation between postural changes in AHI and leg fluid volume was 0.22 (p = 0.42). Changes in leg fluid volume were a slow phenomenon, whereas changes in CSR-CSA severity were almost synchronous with changes in posture.
CONCLUSION: Lateral position causes a reduction in rostral fluid shift compared to the supine position, but this change does not correlate with the corresponding change in CSR-CSA severity. The two changes occur on different time scales. These findings question the role of postural changes in rostral fluid shift as a determinant of corresponding changes in CSR-CSA severity.
PURPOSE:To provide a recombinant DNA useful for the production of interleukin-2, and composed of a vector DNA replicable in a specific gene and the cell of procaryote or eucaryote. CONSTITUTION:Lymphocyte capable of producing mouse interleukin-2 and separated from peripheral blood, lymph node, spleen, etc., is subjected to the mutagenic treatment such as nylon column treatment, enzymatic treatment, etc. to obtain a cell originated from mouse lymphocyte. mRNA is separeted as a fraction corresponding to the 12S fraction from the above cell by sucrose density gradient centrifugation, gel filtration, etc., and a complement DNA is prepared by using the mRNA as the template. A recombinant DNA is prepared from the resultant vector DNA replicable in the gene coding mouse interleukin-2 and in the cell of procaryote or eucaryote. The eucaryote or procaryote transformed by the recombinant DNA is cultured to obtain interleukin-2.
Data were collected in the Pediatric Emergency Injection Unit of Mersin City Training and Research Hospital between October and December 2021. Children aged 6-12 years were included in the study. In the study, the sample was divided into four groups. The study consisted of 180 children, 45 children in each group. Using the randomization program, it was determined which sample group the children would be included in.

In the study, video game playing, kaleidoscope and virtual reality glasses were used as a distraction method for the experimental group. Intramuscular injection (IM) was applied to the control group without any application. The research implementation period lasted an average of one minute. Required ethical permissions were obtained prior to the research. Wong-Baker Faces Pain Scale (WBFPRS) was used to measure pain level and Child Fear Scale (CFS) was used to measure anxiety level in the study. Explanatory information about the application to be made to the children and their parents was given by the researcher, and the consent form was signed by informing them voluntarily. The research data were collected by the researcher by interviewing the children face to face. In line with the data obtained in the study, it was concluded that the descriptive characteristics of the children in the experimental and control groups were similar (p\>0.05). It was concluded that playing video games, kaleidoscope, and virtual reality glasses, among the distraction methods applied in the study, reduced pain and anxiety. It is expected that techniques that reduce pain and anxiety when intramuscular injections are given to children in nursing practices will be used in practice and that these practices will be included in the training of nurses.
Several studies have shown that proper adherence to treatment regimens is essential for the effectiveness of ARV therapy (e.g Wools-Kaloustian et al. 2006). There is also evidence in that in some treatment programs in Africa, adherence rates are not always high (Gill et al. 2005). Even in settings where adherence levels are found to be high, numerous factors have been identified as being relevant, although the causal effects are unknown (Castro, 2006). As ARV treatment programs are scaled up in Africa, it is essential to understand the socio-economic determinants of adherence to ARV treatment, as well as the impact of interventions to support high levels of adherence. A secondary objective of this study is to understand the socio-economic impacts of higher adherence.